Skip to main content

Table 3 Correlation of cell survival with Clinical and Pathological Factors

From: Prospective cohort study using the breast cancer spheroid model as a predictor for response to neoadjuvant therapy – the SpheroNEO study

  Cutoff  
  Mean <35 % ≥35 %  
Characteristics % P n % n % P
All Patients    32 41.0 46 59.0  
Age at diagnosis, years   .877      1.000
  ≤50 51.44   18 41.9 25 58.1  
  >50 52.61   14 40.0 21 60.0  
Mean - 51 51 .817
Range - 21-76 25-78  
Tumor stage   .181      .603
  cT1/T2 49.40   24 42.9 32 57.1  
  cT3/4 60.66   7 33.3 14 66.7  
Nodal status   .813      1.000
  cN+ 50.41   17 40.5 25 59.5  
  cN- 52.20   15 42.9 20 57.1  
Grading   .339      .486
  G1/2 55.34   15 36.6 26 63.4  
  G3 48.09   16 45.7 19 54.3  
  Not documented    -   -   
Histologic type   .569      .439
  Ductal invasive/other 51.25   30 42.9 40 57.1  
  Lobular invasive 58.29   2 25.0 6 75.0  
HR status   .038      .042
  ER+/PR+ 62.49   10 25.6 29 74.4  
  ER+/PR-/Unknown 36.10   7 70.0 3 30.0  
  ER-/unknown/PR+ 47.82   1 50.0 1 50.0  
  ER-/PR- 43.03   12 50.0 12 50.0  
HER2 status   .000      <.0001
  Negative 58.34   17 28.8 42 71.2  
  Positive 30.70   13 81.3 3 18.8  
  1. PR, progesterone receptor; ER, estrogen receptor; HER2, human epidermal growth factor receptor; pCR, pathologic complete response